Emergent BioSolutions Awarded $31 Million Contract for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine

GAITHERSBURG, Md., March 24, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of NuThrax TM (anthrax vaccine adsorbed with CPG 7909 adjuvant), also known as AV7909, the company's next generation anthrax vaccine candidate. The contract, valued at $31 million, consists of a 30-month base period of performance to develop NuThrax for post-exposure prophylaxis of anthrax disease. Activities to be completed under the contract include process validation, consistency lot manufacture, assay validation, non-clinical studies, and start-up activities in preparation for the Phase 3 clinical trial.

"Emergent looks forward to working with BARDA to advance the development of NuThrax towards a Phase 3 study. We are committed to addressing the U.S. government's desire for a next generation anthrax vaccine with an enhanced product profile that includes requiring fewer doses, eliciting a higher immune response, and dispensing the need for cold chain with a dry formulation," said Adam Havey, executive vice president and president biodefense division of Emergent BioSolutions. "Moving to these final stages of development is also made possible by earlier support from the National Institute of Allergy and Infectious Diseases (NIAID) for the early stage development of NuThrax, which led to the successful completion of our Phase 2 clinical study. NIAID is also supporting current efforts to develop a dry formulation for this vaccine candidate."

NuThrax is comprised of BioThrax ® (Anthrax Vaccine Adsorbed) in combination with the immunostimulatory oligodeoxynucleotide compound CPG 7909. In 2014, Emergent successfully concluded a randomized, parallel-group, active-controlled, double-blind Phase 2 study, which was designed to evaluate the safety and immunogenicity of NuThrax for post-exposure prophylaxis of anthrax infection using two- and three-dose immunization schedules and two dose levels. The study results, which were presented at the ASM Biodefense and Emerging Diseases Research Meeting last month, suggest further study of a two-dose schedule of NuThrax in light of the favorable tolerability profile and immunogenicity response relative to three doses of BioThrax.

This contract HHSO100201500004C for the advanced development of NuThrax is funded by BARDA within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (HHS). The Phase 2 clinical trial was conducted with support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) of HHS under development contract number HHSN272201000035C. Contract HHSN272201400038C to develop a dry formulation of NuThrax is also administered through NIAID.

About Emergent BioSolutions

Emergent BioSolutions is a global specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information about the company may be found at www.emergentbiosolutions.com . Follow us @emergentbiosolu.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements containing the words "believes", "expects", "anticipates", "intends", "plans", "estimates" and similar expressions, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including availability of funding for our U.S. government grants and contracts and our manufacturing capabilities and strategy. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 Media Contact: Tracey Schmitt Vice President, Global Public Affairs and Corporate Responsibility 240-631-3394

Scroll down for more posts ▼

Top 10 Most Recent News Articles

APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 81

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 91

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 92

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Join Flywire Corporation Securities Class Action

Updated Category News Views 219

Investors Urged to Join Flywire Corporation Securities Class Action The recent developments surrounding Flywire Corporation (NASDAQ: FLYW) have captured the attention of investors, especially those who purchased securities during the specified period. The Rosen Law Firm, known for championing investor rights, is taking the lead in facilitating a securities fraud lawsuit...

Continue Reading
Unicycive Therapeutics Faces Investigation Over Stock Concerns

Updated Category News Views 231

Unicycive Therapeutics Under Investigation for Securities Fraud In recent developments, Pomerantz LLP has initiated an investigation into the possible fraudulent activities involving Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The inquiry focuses on whether the company and its executives may have violated securities laws, an issue that could have implications for many...

Continue Reading
Investors Urged to Act: Join Wolfspeed's Upcoming Class Action

Updated Category News Views 313

Overview of Wolfspeed's Class Action Wolfspeed, Inc. investors are encouraged to take action regarding their stakes in the company as a class action lawsuit surfaces. The Rosen Law Firm, a reputable entity specializing in investor rights, sets a significant deadline for participation in this case. It’s essential for anyone who purchased shares within the specified...

Continue Reading
Pacsun Champions Co-Creation at Music's Grandest Stage

Updated Category News Views 194

Pacsun Champions Co-Creation at Music's Grandest Stage Youth Retailer Debuts Co-Branded Merchandise and Artist Performances As Grammy Weekend celebrates the top talents in music, Pacsun embraces the opportunity to highlight the emerging artists and professionals shaping the future of music. Their approach emphasizes co-creation, access, and cultural participation, crucial...

Continue Reading
Vistra Corp Enhances Financial Stability with Credit Facility Boost

Updated Category News Views 134

Vistra Corp Strengthens Financial Flexibility In a strategic move to enhance its financial flexibility, Vistra Corp. (NYSE:VST), known for delivering electric services, has taken steps to amend its credit agreement. The changes not only extend the maturity date of its credit facility but also expand its borrowing capabilities. This adjustment, effective October 2, 2024,...

Continue Reading